Profound Medical Corp.

Profound Medical Corp. held its 2026 Annual General and Special Meeting of Shareholders on May 13, 2026. Shareholders elected eight director nominees to the Board, approved the appointment of PricewaterhouseCoopers LLP as auditors, and passed an ordinary resolution to approve all unallocated restricted share units and deferred share units under the company's long-term incentive plan. All proposals presented at the meeting were approved by the security holders.

Profound Medical Corp. announced that its TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's Annual Meeting on May 16, 2026. The company also revealed an initiative to explore integrating PSMA PET molecular imaging technologies with the TULSA Procedure to enhance treatment planning and patient monitoring for prostate ablation. This development aims to empower physicians with greater precision and confidence in delivering tailored treatments.

Profound Medical Corp. reported a significant improvement in its financial performance for the first quarter ended March 31, 2026. The company's revenue more than doubled, increasing by 104% to $5.337 million, driven by higher recurring and capital sales in the United States and overseas. Concurrently, the net loss for the period narrowed by 34% to $7.053 million, and the basic and diluted loss per share improved by 47% to $0.19. Operating expenses also saw a reduction, contributing to the improved profitability.

Profound Medical Corp. reported strong first-quarter 2026 financial results, with revenue increasing 104% year-over-year to $5.3 million and a 34% improvement in net loss to $7.0 million. The company also announced that Humana has become the first national payor in the U.S. to cover the TULSA Procedure, adding approximately 8.5 million covered lives. Profound issued full-year 2026 revenue guidance of approximately $25 million, representing 56% growth.

Profound Medical Corp. announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the financial performance and business developments during the period. Investors can access the call via dial-in numbers or a live webcast.

Profound Medical Corp. announced it will provide a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference. The presentation is scheduled for Wednesday, April 22, 2026, at 10:00 a.m. Eastern Time. Investors can attend in person at the Metro Toronto Convention Centre or view a live broadcast, offering insights into the company's current operations and strategic direction.

Profound Medical Corp. announced it will provide a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference. The presentation is scheduled for Wednesday, April 22, 2026, at 10:00 a.m. Eastern Time. This event offers the company an opportunity to engage with investors and provide insights into its current operations and strategic direction.